Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
about
Adaptive immunity in the liverPotentiality of immunotherapy against hepatocellular carcinomaImmunology of hepatocellular carcinomaImmune checkpoint blockade in hepatocellular carcinoma: current progress and future directionsSignificant roles of regulatory T cells and myeloid derived suppressor cells in hepatitis B virus persistent infection and hepatitis B virus-related HCCsA different representation of natural T cells and natural killer cells between tumor-infiltrating and periphery lymphocytes in human hepatocellular carcinoma.Cluster of differentiation 45 activation is crucial in interleukin-10-dependent tumor-associated dendritic cell differentiation.Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms.Intratumoral dendritic cells in the anti-tumor immune responseIdentification of a FOXP3(+)CD3(+)CD56(+) population with immunosuppressive function in cancer tissues of human hepatocellular carcinoma.Tolerogenic dendritic cells and their applications in transplantationCD14(+) regulatory dendritic cells in patients with hepatocellular carcinoma and cirrhosis.Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.Tumoral indoleamine 2, 3-dioxygenase 1 is regulated by monocytes and T lymphocytes collaboration in hepatocellular carcinoma.Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment.Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation.Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma.Significant biomarkers for the management of hepatocellular carcinoma.Immunological landscape and immunotherapy of hepatocellular carcinoma.Immunotherapy in hepatocellular carcinoma: Primed to make a difference?Immunosuppressive cells in tumor immune escape and metastasis.Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments.Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies.Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancerCurrent immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions.Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?Generation of regulatory dendritic cells after treatment with paeoniflorin.Postoperative aspartate aminotransferase to lymphocyte ratio index change is an independent predictor of survival in patients with small hepatocellular carcinoma.Targets for immunotherapy of liver cancer.Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells.Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review.Role of nonresolving inflammation in hepatocellular carcinoma development and progression.Immunotherapy of hepatocellular carcinomaHuman hepatocellular carcinoma-infiltrating CD4⁺CD69⁺Foxp3⁻ regulatory T cell suppresses T cell response via membrane-bound TGF-β1Potentiating cancer vaccine efficacy in liver cancer
P2860
Q26753195-B07C3A2B-9D95-49B2-BC9A-26651345A578Q26784228-25C3338B-327A-408A-9A39-87F8126E8DD7Q26795411-3845D7F8-1A7D-4F08-B884-8F193E349572Q26865859-F4BB95D0-AACE-4262-BA59-5DE4F8D88DF8Q28086980-DD90A4A1-57FC-4A2A-972F-46FD6AE4A53DQ33685646-34060C52-4968-4960-9FC4-86477A80C24BQ33844094-4A8014DF-F60A-4D9C-97A9-AFAB12F978EFQ35528377-207C9A1C-E8D5-4E0C-80EE-D58432FCD2DCQ35833610-6E0F16B9-05C5-4927-9821-FBBE4257CEAAQ36123388-39FCEF10-84C0-4D73-858F-98E7342236F7Q36302853-82F9179E-8164-40C8-AE28-0FA396B7D24FQ36723045-11858E66-080D-48A9-9934-552A7B37DAF8Q36910715-623B3EB7-1D69-46F0-9C5E-F3D856F9D1EAQ36998864-2FEEBD36-9AC5-465A-B5BB-39BB7759F38AQ37046717-3ED78032-D907-4AC8-A2A6-0C4273456820Q37098079-BE1DAB35-CDFF-4301-B453-49602DE4AC4FQ37499246-E657B92C-A770-4E58-ACF0-99DBD25CF7C2Q37742979-62AFB76C-280D-49C5-A2B8-F804ABCE0C28Q38412315-77F0E928-B1E2-4BDE-ADC2-DC9E3505078BQ38611895-D660B24C-F410-4266-A5FE-8A41CEA74950Q38625948-1BBF04B6-F76A-436E-806E-C8ABBFAD6190Q38675140-6C595D18-3559-41C4-9702-59EE4F860359Q38728953-BABC171F-6C30-4E59-86CC-F2F04C3D6939Q38754730-0EA4E8A1-2A1A-49F7-BC68-82F8A0CFDC22Q39458547-A9D57F4A-1813-4CBE-90AF-70DD445034D4Q39535683-C5EA2493-005D-4CBA-A4CA-CBC99DD92440Q40713858-3C72D322-6E1A-4C7E-B203-09633B5F4E21Q42216809-D8024AC4-5445-493B-A370-2F8EA9434387Q42375643-D7F083CC-47AF-4A81-A8E6-6223AFF8B705Q45070547-E411D292-9101-4480-AAC9-63C9F00B1F7DQ47348999-535FEF56-2D0C-4589-B730-4C609026FCFBQ47597883-45E6E678-0366-49C3-B5A5-441B7741A90BQ47965755-B16B6B33-88E3-4F3B-8641-810DD2D96758Q50034338-43876210-6339-4B72-9695-735932CF9158Q54963955-42995A06-4DA1-46E0-BAD4-524C8F33F94BQ55268879-C2E0955C-AF96-44E5-9828-A30D09E2925AQ55288642-D21057A7-6BE9-4363-BBCD-A4E87F492C28Q56896669-CC78F5D5-C109-44CF-8FDF-AB326CCAC0A1Q56896907-7108D067-1A97-414F-93E2-7D6E4B050618Q57138867-CE9FDC25-4C9F-4A0C-AF8F-CF7A0AD98800
P2860
Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Human CD14+ CTLA-4+ regulatory ...... n in hepatocellular carcinoma.
@ast
Human CD14+ CTLA-4+ regulatory ...... n in hepatocellular carcinoma.
@en
Human CD14+ CTLA-4+ regulatory ...... n in hepatocellular carcinoma.
@nl
type
label
Human CD14+ CTLA-4+ regulatory ...... n in hepatocellular carcinoma.
@ast
Human CD14+ CTLA-4+ regulatory ...... n in hepatocellular carcinoma.
@en
Human CD14+ CTLA-4+ regulatory ...... n in hepatocellular carcinoma.
@nl
prefLabel
Human CD14+ CTLA-4+ regulatory ...... n in hepatocellular carcinoma.
@ast
Human CD14+ CTLA-4+ regulatory ...... n in hepatocellular carcinoma.
@en
Human CD14+ CTLA-4+ regulatory ...... n in hepatocellular carcinoma.
@nl
P2093
P2860
P356
P1433
P1476
Human CD14+ CTLA-4+ regulatory ...... on in hepatocellular carcinoma
@en
P2093
Minghong Jiang
Weiping Zhou
Xuetao Cao
Yanmei Han
Zhengping Jiang
P2860
P304
P356
10.1002/HEP.26694
P407
P50
P577
2013-12-23T00:00:00Z